Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Inke S.A: APIs manufacturing plant.

    Virtual Booth

    Contact Supplier

    xyz-pharma-2025-04-21

    Virtual Booth

    An Enquiry

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-04-28

    Virtual Booth

    An Enquiry

    Menu

    Elraglusib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Actuate to Present Elraglusib Phase 2 Data at 2025 ASCO Meeting
    Actuate to Present Elraglusib Phase 2 Data at 2025 ASCO Meeting

    23 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/23/3066581/0/en/Actuate-to-Present-Elraglusib-Phase-2-Topline-Data-at-the-2025-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting.html

    GLOBENEWSWIRE
    23 Apr 2025
    Share Share
    Actuate to Present Data on Elraglusib in Salivary Gland Carcinoma
    Actuate to Present Data on Elraglusib in Salivary Gland Carcinoma

    17 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/17/3063291/0/en/Actuate-to-Present-Promising-Data-on-Elraglusib-in-Advanced-Salivary-Gland-Carcinoma-at-the-AACR-Annual-Meeting-2025.html

    GLOBENEWSWIRE
    17 Apr 2025
    Share Share
    Actuate Completes Enrollment In Ph II Elraglusib Pancreatic Cancer
    Actuate Completes Enrollment In Ph II Elraglusib Pancreatic Cancer

    25 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/02/25/3031941/0/en/Actuate-Announces-Completion-of-Enrollment-in-a-Phase-2-Trial-of-Elraglusib-in-Combination-with-FOLFIRINOX-and-Losartan-in-Patients-with-Previously-Untreated-Metastatic-Pancreatic-.html

    GLOBENEWSWIRE
    25 Feb 2025
    Share Share
    Actuate Receives EMA Orphan Status For Elraglusib In Cancer
    Actuate Receives EMA Orphan Status For Elraglusib In Cancer

    07 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/07/3005368/0/en/Actuate-Therapeutics-Receives-EMA-Orphan-Medicinal-Product-Designation-for-Elraglusib-for-the-Treatment-of-Pancreatic-Cancer.html

    GLOBENEWSWIRE
    07 Jan 2025
    Share Share
    Actuate Therapeutics Announces Interim Data for Elraglusib
    Actuate Therapeutics Announces Interim Data for Elraglusib

    17 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/17/2998254/0/en/Actuate-Therapeutics-Announces-Positive-Interim-Phase-2-Data-of-Elraglusib-in-First-Line-Treatment-of-Metastatic-Pancreatic-Cancer.html

    GLOBENEWSWIRE
    17 Dec 2024
    Share Share
    Actuate Gets FDA Rare Pediatric Designation for Elraglusib
    Actuate Gets FDA Rare Pediatric Designation for Elraglusib

    12 Nov 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/11/12/2979076/0/en/Actuate-Announces-FDA-Rare-Pediatric-Disease-Designation-Granted-to-Elraglusib-for-Treatment-of-Ewing-Sarcoma.html

    GLOBENEWSWIRE
    12 Nov 2024
    Share Share